Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Fiche publication
Date publication
mars 2024
Journal
The lancet. Healthy longevity
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine
Tous les auteurs :
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A,
Lien Pubmed
Résumé
At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population.
Mots clés
Humans, Male, Aged, Female, Methotrexate, adverse effects, Squamous Cell Carcinoma of Head and Neck, drug therapy, Cetuximab, adverse effects, Frail Elderly, Head and Neck Neoplasms, drug therapy, Disease Progression, Fatigue
Référence
Lancet Healthy Longev. 2024 03;5(3):e182-e193